Matinas BioPharma Holdings

Company snapshot

Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique character

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Matinas BioPharma Holdings. Not investment advice.

• Peer + 0 momentum

  Arrowhead Pharmaceuticals Ireland

  TA overlap score 32.6

Recent activity

Latest pipeline, patent, and corporate events for Matinas BioPharma Holdings.

1. Jun 8, 2026 Clinical update

   Oral Encochleated Amphotericin B (CAMB) — Phase 2

2. Jun 8, 2026 Clinical update

   Oral Encochleated Amphotericin B (CAMB) — Phase 2

3. Jun 8, 2026 Clinical update

   Oral Encochleated Amphotericin B (CAMB) — Phase 2

4. Jun 8, 2026 Clinical update

   Omega 3 pentaenoic acid — Phase 2

5. Jun 5, 2026 Clinical update

   Placebo — Phase 3

View all clinical trial activity →

• What is Matinas BioPharma Holdings?

  Matinas BioPharma is a biotech organization headquartered in Bedminster, USA. It trades on NYSE under ticker MTNB. Primary therapeutic focus areas include Hypertriglyceridemia, Candidiasis, Chronic Mucocutaneous, Cryptococcal Infections, Cryptococcal Meningitis, Acute Myeloid Leu

• Is Matinas BioPharma Holdings publicly traded?

  Yes. Matinas BioPharma Holdings is listed with ticker MTNB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Matinas BioPharma Holdings develop or market?

  We link 5 drug profile(s) where Matinas BioPharma Holdings is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/matinas-biopharma-holdings#company-drugs.

• What are the latest developments for Matinas BioPharma Holdings?

  In the last 12 months our linked public records show 9 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Matinas BioPharma Holdings focus on?

  Matinas BioPharma Holdings focuses on Hypertriglyceridemia, Candidiasis, Chronic Mucocutaneous, Cryptococcal Infections based on our analysis of their pipeline programs and drug development activities.